Unitree Robotics has shed $35 billion in market capitalization since its August 2026 debut on the Shanghai Stock Exchange, with shares closing at 47% of their initial offering price as of market close September 12. The Hangzhou-based manufacturer of quadruped and humanoid robots opened trading last month at a valuation of $66 billion, a figure that placed it among the most richly valued private robotics companies to go public in China. That valuation has now contracted to roughly $31 billion, erasing gains for retail investors who participated in the oversubscribed offering and putting pressure on institutional backers who supported the IPO pricing.
The decline reflects broader skepticism about whether Unitree can sustain the growth trajectory implied by its initial valuation. The company generated approximately $580 million in revenue over the twelve months ending June 2026, according to figures disclosed in its IPO prospectus, which means the initial $66 billion valuation represented a price-to-sales multiple north of 110x. Even after the 53% drawdown, shares trade at roughly 53 times trailing revenue, a premium that exceeds publicly traded peers including Boston Dynamics' parent company Hyundai Motor Group and Agility Robotics, which completed its own public listing in March 2026 at a $4.8 billion valuation. Unitree's revenue base consists primarily of sales of its Go2 and B2 quadruped platforms to research institutions, along with a smaller but growing share from its G1 humanoid robot, which began shipping to enterprise customers in limited quantities during the second quarter. The company has not disclosed profitability metrics, and analysts estimate it is burning between $40 million and $60 million per quarter as it scales manufacturing capacity and invests in AI-driven autonomy software.
The Shanghai listing came at a moment of heightened enthusiasm for humanoid robotics in China, where government policy has explicitly prioritized the sector as part of the country's broader push into advanced manufacturing and AI. Unitree positioned itself during the roadshow as the domestic answer to Figure AI and Tesla's Optimus program, emphasizing its ability to deliver capable humanoid hardware at price points below $20,000 per unit for the G1 platform. That pitch resonated with retail investors, who subscribed to the IPO at rates exceeding 60 times the available allocation, forcing underwriters to scale back individual orders. Institutional participation, however, was more muted, with several large Chinese technology funds declining to anchor the deal, citing concerns about Unitree's ability to defend margins as competitors including Xiaomi, Fourier Intelligence, and UBTECH Robotics ramp their own humanoid platforms. The pricing reflected those tensions: underwriters initially targeted a $45 billion to $55 billion valuation range before elevating the final price in response to retail demand, a decision that now appears to have misjudged institutional appetite for holding shares beyond the first-day pop.
What distinguishes Unitree's post-IPO performance from typical volatility is the speed and magnitude of the retreat. Chinese IPOs frequently experience first-week corrections as momentum traders exit positions, but a 53% decline within 30 days places Unitree among the poorest debuts of 2026 across all sectors. The sell-off accelerated following a September 4 research note from CICC, one of the IPO's underwriters, which downgraded its price target by 40% after the company disclosed weaker-than-expected August shipment figures for the G1 humanoid. Unitree had projected 1,200 G1 units would ship in August; actual deliveries totaled 680 units, a shortfall the company attributed to supply chain constraints affecting actuator procurement and longer-than-anticipated integration timelines for enterprise customers deploying the robots in warehouse and inspection applications. The actuator issue is particularly significant because Unitree manufactures its own joint modules in-house, a vertically integrated approach the company promoted as a competitive advantage during the IPO process. If the bottleneck persists into the fourth quarter, Unitree may miss its full-year guidance of 9,000 G1 units, a target that underpins revenue projections for fiscal 2027 and factors heavily into the growth assumptions embedded in even the current, reduced valuation.
What to Watch: Monitor whether Unitree adjusts its full-year unit shipment guidance during its November earnings call, particularly for the G1 humanoid platform where production delays have already surfaced. Track actuator supply announcements from the company or reports of capacity expansions at its Hangzhou manufacturing facilities. Watch for secondary offerings or insider sales during the lockup expiration window in February 2027, which will signal whether early investors and employees view the current price as stabilized or expect further declines. Pay attention to competitive pricing moves from UBTECH and Fourier Intelligence, both of which are reportedly preparing humanoid product launches before year-end that could further compress Unitree's margin assumptions.
